Related Experiment Video
Updated: Aug 8, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Abstract:
Fourteen patients with acute deep vein thrombosis (DVT) of the thigh were treated with different doses of streptokinase (SK) as a local venous infusion. Only the lowest SK-dose given, 4,000 U/h for 72 h, had any effect. Three out of 9 patients on this dose showed significant lysis. However, systemic hemorrhagic side effects occurred in 3 patients, local dermatitis in another 3. The reason for the limited thrombolytic effect and systemic side effects could be that the catheter is not in the immediate vicinity of the thrombus, and that the SK-infusion by-passes the occluded vein segments through collaterals. There is probably no advantage of local venous SK-infusion over systemic SK-therapy in DVT.
Insights
Local venous streptokinase (SK) infusion for thigh deep vein thrombosis (DVT) showed limited efficacy and side effects. The lowest dose had minimal effect, suggesting no advantage over systemic therapy for DVT treatment.
Area of Science:
- Vascular Medicine
- Thrombosis Research
- Pharmacology
Background:
- Deep vein thrombosis (DVT) is a significant vascular condition requiring effective treatment.
- Thrombolytic therapy aims to dissolve blood clots, but its optimal delivery method for DVT remains under investigation.
- Streptokinase (SK) is a thrombolytic agent with potential applications in DVT management.
Purpose of the Study:
- To evaluate the efficacy and safety of local venous streptokinase (SK) infusion for acute deep vein thrombosis (DVT) of the thigh.
- To determine the optimal dose and duration for local SK infusion in DVT treatment.
- To compare the effectiveness and side effect profile of local venous SK infusion versus systemic SK therapy.
Main Methods:
- Fourteen patients with acute thigh DVT were enrolled.
- Treatment involved local venous infusion of varying streptokinase (SK) doses.
- The lowest effective dose was identified as 4,000 U/h for 72 hours.
Main Results:
- Only the lowest SK dose (4,000 U/h for 72 h) demonstrated significant thrombolysis in 3 out of 9 patients.
- Systemic hemorrhagic side effects were observed in 3 patients.
- Local dermatitis occurred in 3 patients, indicating adverse reactions to the infusion.
Conclusions:
- Local venous SK infusion for thigh DVT shows limited efficacy and carries risks of systemic and local side effects.
- The catheter placement and collateral circulation may hinder effective thrombolysis.
- There is likely no significant advantage of local venous SK infusion over systemic SK therapy for DVT.
Related Concept Videos
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

